Biotechnology company ALSEN reported on Monday the addition of Edwin Moses as chairman of its board of directors.
Most recently, Dr Moses has served as chairman and CEO of Ablynx over 14 years, leading its rapid growth from a small research-focused organization to one of Europe's most successful biotechnology companies, until its acquisition by Sanofi in 2018.
Previously, Dr Moses worked as the CEO and chairman at Oxford Asymmetry International between 1993-2001.
Currently, Dr Moses is the chairman of Achilles Therapeutics Ltd, Avantium NV and LabGenius Ltd as well as an operating partner at Keensight Capital.
TiumBio files Clinical Trial Application to start Phase 1b TU7710 study
Moderna reports positive interim results from next-generation COVID-19 vaccine trial
Scancell initiates SCOPE trial's iSCIB1+ cohort
Valneva launches Phase 1 trial for next-generation Zika vaccine
argenx obtains VYVGART approval for primary immune thrombocytopenia in Japan
Bio-Thera Solutions' BAT8006 phase II Study receives US FDA IND approval